Skip to content

Interest in Nighttime Day Hospital Chemotherapy Infusions Among Gynecologic Cancer Patients

Assessment of Interest Among Patients With Gynecologic Cancers in a Nighttime Day Hospital (DH) Service for Long-duration Chemotherapy Infusions: an Observational Study Based on an Anonymous Online Survey.

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07483905
Acronym
CHeMoON
Enrollment
200
Registered
2026-03-19
Start date
2026-03-12
Completion date
2026-07-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecologic Cancers

Keywords

Long-duration Chemotherapy, Nighttime Day Hospital, Cancer Care Organization, Patient Preferences

Brief summary

This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. An anonymous online survey will be distributed to eligible patients to evaluate their preferences, perceived benefits, and potential barriers related to receiving chemotherapy during nighttime hours. The results of this study will help inform the feasibility and acceptability of implementing a nighttime Day Hospital service for prolonged chemotherapy infusions.

Detailed description

Long-duration chemotherapy infusions are increasingly used in the treatment of gynecologic cancers. These treatments often require prolonged administration times that may extend over several hours and may affect patients' daily activities and quality of life when delivered during standard daytime hospital schedules. The implementation of a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions could represent an alternative organizational model aimed at improving patient convenience and optimizing hospital resource utilization. However, the acceptability of such a service from the patients' perspective has not been well explored. This observational study will evaluate the interest and perceived acceptability of a nighttime Day Hospital service among patients with gynecologic cancers who may receive long-duration chemotherapy infusions. Data will be collected through an anonymous online survey administered to eligible patients. The questionnaire will explore patient preferences, potential advantages and disadvantages, logistical considerations, and willingness to receive chemotherapy during nighttime hours. The results of this study may provide preliminary information on patient perspectives and help inform future organizational strategies for the delivery of prolonged chemotherapy infusions.

Interventions

BEHAVIORALonline survey

Participants will complete an anonymous online survey designed to assess their interest in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions.

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female patients * aged 18 years or older * Diagnosis of a gynecologic cancer * Receiving care at the participating institution * Ability to independently understand and complete complete the anonymous online survey

Exclusion criteria

* Inability to access or complete the online questionnaire or difficulty with reading and writing * Cognitive impairment * Patients currently hospitalized or in emergency settings.

Design outcomes

Primary

MeasureTime frameDescription
Level of patient interest in a nighttime Day Hospital service for long-duration chemotherapy infusionsBaselineAssessment of the level of interest among patients with gynecologic cancers in receiving long-duration chemotherapy infusions during nighttime hours in a Day Hospital setting, as evaluated through responses to an anonymous online survey.

Countries

Italy

Contacts

CONTACTAnna Fagotti
anna.fagotti@policlinicogemelli.it+390630153502
CONTACTSerena Maria Boccia
serenamaria.boccia@policlinicogemelli.it
PRINCIPAL_INVESTIGATORAnna Fagotti

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026